SCHEMBL15517656

SCHEMBL15517656

Cc1cccc(C2CCOC2)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
MAP3K14 Q99558 1/20 0.39
TRPA1 O75762 1/20 0.38
HTR2C P28335 5/20 0.37
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
HPGD P15428 2/20 0.33
PDE10A Q9Y233 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
F2 P00734 2/20 0.33
PLG P00747 2/20 0.33
PLAU P00749 2/20 0.33
PLAT P00750 2/20 0.33
KLK1 P06870 2/20 0.33
PRSS1 P07477 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21884033 0.86 ALDH1A1 (0.48) ALDH1A1MAP3K14TRPA1HTR2CGABRA1
SCHEMBL9495545 0.83 HTR2C (0.54) MAP3K14HTR2CPDE10A
SCHEMBL28452283 0.82 HTR2C (0.52) HTR2CPDE10A
SCHEMBL31546566 0.80 CD44 (0.38) MAP3K14HTR2CPDE10A
SCHEMBL930208 0.80 ALDH1A1 (0.54) ALDH1A1MAP3K14TRPA1HTR2CGABRA1
SCHEMBL27857366 0.78 ALDH1A1 (0.52) ALDH1A1MAP3K14TRPA1HTR2CGABRA1
SCHEMBL466853 0.77 ALDH1A1 (0.50) ALDH1A1TRPA1HTR2CGABRA1GABRB2
SCHEMBL23258492 0.77 DBH (0.38) PDE10AF2PLGPLAUPLAT
SCHEMBL15517621 0.77 UGT2B17 (0.37) ALDH1A1KDM4EF2PLGPLAU
SCHEMBL23250754 0.77 DBH (0.38) PDE10AF2PLGPLAUPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2890677-B1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-11-15 EP disclosed
US-9447083-B2 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-09-20 US disclosed
US-9447083-B2 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-09-20 US disclosed
US-9447083-B2 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-09-20 US disclosed
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-10 US disclosed
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-10 US disclosed
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-10 US disclosed
EP-2890677-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG Chong Kun Dang Pharmaceutical Corp. (KR) 2015-07-08 EP disclosed
WO-2014035149-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG MALT1, MCL1, ACIN1 ALDH1A1 769/4885MAP3K14 3452/4885TRPA1 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.